We power innovation

Complementary to its well-established range of upstream bioprocessing solutions to produce viral vectors for Gene and Cell therapies, Polyplus® has been developing non-viral delivery solutions for over 20 years, helping to meet the challenges of in vitro, ex vivo and in vivo gene delivery.

Enabling RNA/DNA therapeutics development from Discovery to Human clinical trials. Our portfolio includes a wide range of products, from the gold standard cationic polymer-based in vivojetPEI®, which is ready-to-use and ensures the delivery of any type of nuclec acids, to ready-to-use lipid-based nanoparticles: in vivo-jetRNA®+, dedicated to the delivery of mRNA both in vivo and ex vivo, and cationic lipids used as bricks to formulate and improve lipid nanoparticles (LNPs) formulation to open up new possibilities for mRNA-based therapies.


in vivojetPEI®is a ready-to-use cationic polymer reagent dedicated to the in vivo delivery of all types of nucleic acids (eg. DNA, siRNA, miRNA, oligonucleotides, etc.). It has been successfully used over the years in multiple studies and cited in over 600 peer-reviewed publications. Reagent’s efficiency, safety and GMP grade availability have also made it the delivery vector of choice for several clinical trials in different phases (from preclinical to phase III). 


LipidBrick® library : Lipid-based nanoparticles (LNPs) represent one of the most promising RNA delivery systems, not only due to their efficacy, but also to the ease of production achieved through precise controlled mixing technique known as microfluidics and the scalability of production. Still, they present some limitations related to toxicity, targeting, limited biodistribution through systemic administration which mainly results in liver uptake. For this purpose, Polyplus® has recently developed a library of cationic lipids (LipidBrick®), which represents a remarkable innovation compared with conventional cationic lipids by ensuring reduced toxicity of LNPs and extending their use beyond the liver.  

in vivo-jetRNA®+ : As an alternative to LNPs, we have also developed a ready-to-use lipid based transfection reagent in vivo-jetRNA®+ consisting of lipid-based nanoparticles specifically engineered to deliver mRNA and saRNA. This reagent is very efficient and leads to gene expression comparable to LNPs in vivo and ex vivo. It can therefore be used as a ready-to-use formulation for immunizations purposes, proof-of-concept studies, or to benchmark LNP formulations under development for in vivo or ex vivo applications. 

Selecting the right approach for RNA therapeutics

Selecting the right approach for RNA therapeutics involves a careful consideration of various factors, including the target disease, the type of RNA molecule you want to target, the delivery method, and the specific therapeutic strategy.
At Polyplus®, we offer different types of non-viral delivery solutions to enable you to select the most suitable option for your needs and to support you throughout the development of your innovative RNA therapies!

Webinar replay : Fine-tuning your mRNA-LNP formulation with an innovative cationic lipid library

Watch Webinar

Start your journey with an overview on how cationic lipids offer new possibilities in lipid-based nanoparticles and LNP engineering for RNA therapeutics

Watch Webinar

Discover Our Applications

Cell & Gene Therapy

Success of Gene and Cell Therapies is dependent on efficient production of viral vectors that require optimized transfection reagents and viral vector engineering

Protein Production

Broad range of solutions is needed for manufacturing of functional  proteins or antibodies at the desired scale in bacteria, yeast and mammalian cell expression systems

Life Sciences

Optimised plasmid engineering and specific transfection reagents are key to enable protein expression in a wide range of adherent and suspension mammalian cell types